SlideShare uma empresa Scribd logo
1 de 31
Baixar para ler offline
Opioid Dependence: Health
Plan Problems and Strategies


    Kelly J. Clark, MD, MBA, DFAPA, FASAM
     Medical Director of Behavioral Health
                CDPHP, Albany NY
Disclosure Statement
•  All presenters for this session, Dr. Kelly J.
   Clark and Dr. Nathaniel P. Katz, have
   disclosed no relevant, real or apparent
   personal or professional financial
   relationships.
Learning Objectives:
•  1. Identify barriers to responsible pain management that
   does not contribute to an addiction or to diversion
   activities.

•  2. Outline best practice strategies for patient monitoring
   to prevent over-prescribing and dispensing.

•  3. Explain the importance of coordinating care between
   health care providers and facilities.
Health Plan concerns:
•  Value = Quality / Cost

•  Behavioral Health = Mental Health, SUDs and
   Health Behaviors

•  Total Cost of Care:
   –  Primary Care Physician   - Hospital
   –  Specialist               - non-MD providers
   –  Pharmacy                 - Imaging
   –  ER and Urgent care       - labs
Barriers to responsible pain management,
                      or
Why might MD s overprescribe?

   •  Lack of information

   •  Lack of skill

   •  External reinforcement
Lack of information

- What are proper prescription patterns

- Which patients are at risk for problems

- Whether a patient has demonstrated a problem

- Where they can access expert consultation
Lack of skill

–  Managing patient expectations

–  Confronting problematic patient behaviors

–  Working collaboratively with other providers

–  Using a biopsychosocial approach
External reinforcement

- Payment models rewarding more quickly
writing pills than talking with patients

- The Fifth Vital Sign   quality metric

- Pay for high patient satisfaction
Health Plans:
           Keepers of the Data

•  Claims data from all areas:
  –  Primary Care Physician   - Hospital
  –  Specialist               - Labs
  –  Pharmacy                 - Imaging
  –  ER and Urgent care       - non-MD providers


•  These can be used by individual providers and
   larger systems to improve care and decrease
   cost
Uses of plan data:
 population management issues

•  Health plan data can show the range of practice
   patterns in a community

•  UDS claims study

•  Example emergency department utilization to
   obtain controlled drug rx
Trust, but Verify: the UDS
•  Urine Drugs Screens should be like a blood
   glucose level

•  Clinicians need to understand what yields false
   positives and false negatives

•  Who is at risk for substance misuse?
  –  humans
CDPHP

•  Regional, non-profit, physician-directed health plan
         (Albany, NY)

•  350,000 covered lives

•  All LOB (Medicare, Medicaid, Commercial, ACO)
Rates of Drug and/or
          alcohol screenings

–  Continuously enrolled for 12 months

–  275 days of fill of any controlled substance (75%)

–  drug screening code 80100/80101,G0434,G0431
Results : 1 year controlled drug use
              and UDS

   •  Medicaid population = 16.8% members
   •  Medicaid population = 27.9% 1 year Rx



   •  7.6% of all members with chronic prescriptions
      had a drug screen within the year
Use of ER to obtain
            controlled drug Rx
•    Claims data from first 6 months of 2011
•    ER claims
•    Fills for controlled drugs within 2 days of ER visit
•    Voluntary inpatient admissions for detoxification or
     substance abuse rehabilitation
1 visit with a prescription
3 visits with a prescription
If an ER doc gives
       a controlled drug prescription:

•  1/58 of our commercial members they give it to use the
   ER three times January to July

•  1/9 of our Medicaid/FHP members they give it to use the
   ER three times January to July for controlled drugs.

•  Or, 1/37 of the Medicaid/FHP members in an ER right
   now use the ER 3 times for controlled drug from
   January to July
Addiction admissions who
   obtained rx from ER
Intermittent Schedule of Reinforcement


- 4.1 pills per rx is the average of the top 10 ER
  prescribers

- 20 pills or more are given in 1/15 total ER prescription

- The variability in practice pattern is high, and inversely
  related to numbers of prescriptions written
Plan data can drive education
            and policy

-Educating ER prescribers on practice patterns
-Altering policies measuring quality in ERs
-Educating all prescribers on need for UDS
  (including ER docs)
-provider systems can work with plans to get the
  data needed
Plan strategies: working with
providers to improve monitoring and
     decrease over-prescribing

   •    Information exchange
   •    Care Coordination
   •    Prior Approval
   •    Pharmacy management
   •    Innovative payment programs
Health plan tools:
     Information exchange

Primary Care Physician could get info if:
   • Pt seen in ER
   • Pt admitted to hospital
   • Pt filled Prescriptions
   • Pt seen by specialists
   • Pt had imaging
Health Plan tools:
              Care Coordination

•  calls between providers

•  calls to patients

•  helping support adherence

•  helping support access to ancillary services
    –  (often social services or behavioral health)
Health Plan tools:
               Prior Approval

•  Stops unnecessary re-imaging for pain complaints

•  Pharmacy management
    –  Can be a quality reinforcer
Health Plan tools:
           Pharmacy management
•  Monitors for abuse/diversion
    –  # of prescriptions, # of prescribers, # of pharmacies, # of pills, #
       of meds in each class

•  Quantity limits (# pills, # Rxs)

•  Block payments for prescriptions
    –  Restrict pharmacy, prescribers, pills, facilities

•  Feedback to prescribers
Health plan tools:
   Innovative payment programs

- bundled payments for multidisciplinary pain programs

- buprenorphine spoke-and-wheel

- behavioral medicine and/or care coordination as part of
   PCMH
Best Strategies:
•  Obtain objective information on your patients:
   –  UDS
   –  where they are seen, by whom, with what treatment
•  Obtain collaboration with addictionist experts:
   –  ASAM
   –  PCSS
•  As payment reform happens, work with payers:
   –  Develop the programs your community needs
   –  Look at total cost of care ( ER, inpatient, Labs,
      pharmacy, imaging, as all related to MH/SUDs)
Network for assistance

•  www.asam.org
Addiction physician s medical society

•  http://www.pcssprimarycare.org/
 Provides addictionist mentors for PCPs

Mais conteúdo relacionado

Mais procurados

Closing the Loop: Strategies to Extend Care in the ED
Closing the Loop: Strategies to Extend Care in the EDClosing the Loop: Strategies to Extend Care in the ED
Closing the Loop: Strategies to Extend Care in the EDEngagingPatients
 
UK Presentation September 2014 pdf
UK Presentation September 2014  pdfUK Presentation September 2014  pdf
UK Presentation September 2014 pdfCraig Tanio
 
Quality Use of Medicines
Quality Use of MedicinesQuality Use of Medicines
Quality Use of Medicineskbaskett
 
The Beryl Institute 2013 State of the Patient Experience Benchmarking Study
The Beryl Institute 2013 State of the Patient Experience Benchmarking StudyThe Beryl Institute 2013 State of the Patient Experience Benchmarking Study
The Beryl Institute 2013 State of the Patient Experience Benchmarking StudyEngagingPatients
 
Mhealth for improved medication adherence
Mhealth for improved medication adherenceMhealth for improved medication adherence
Mhealth for improved medication adherenceRamkumar Kannan
 
The NHS’ vision for medicines optimisation - the role for pharma in driving ...
The NHS’ vision for medicines optimisation -  the role for pharma in driving ...The NHS’ vision for medicines optimisation -  the role for pharma in driving ...
The NHS’ vision for medicines optimisation - the role for pharma in driving ...PM Society
 
Gamification as a means to manage chronic disease
Gamification as a means to manage chronic diseaseGamification as a means to manage chronic disease
Gamification as a means to manage chronic diseaseEngagingPatients
 
London Final Copy
London Final CopyLondon Final Copy
London Final CopyJohn Lyttle
 
Emerging Technologies for Patient Engagement and Mobile Health
Emerging Technologies for Patient Engagement and Mobile HealthEmerging Technologies for Patient Engagement and Mobile Health
Emerging Technologies for Patient Engagement and Mobile HealthP. Kenyon Crowley
 
The 5 big pitfalls to avoid for successful patient support programmes", by Na...
The 5 big pitfalls to avoid for successful patient support programmes", by Na...The 5 big pitfalls to avoid for successful patient support programmes", by Na...
The 5 big pitfalls to avoid for successful patient support programmes", by Na...Ashfield, part of UDG Healthcare
 
Medicines Reconciliation Needs You!
Medicines Reconciliation Needs You!Medicines Reconciliation Needs You!
Medicines Reconciliation Needs You!NHSScotlandEvent
 
Genesis Presentation
Genesis PresentationGenesis Presentation
Genesis PresentationHai Duong
 
Automating ED Patient Follow-Up: INFOGRAPHIC
Automating ED Patient Follow-Up: INFOGRAPHICAutomating ED Patient Follow-Up: INFOGRAPHIC
Automating ED Patient Follow-Up: INFOGRAPHICEngagingPatients
 
2015 ihi international forum shadowing poster
2015 ihi international forum shadowing poster2015 ihi international forum shadowing poster
2015 ihi international forum shadowing posterEngagingPatients
 
Workshop 2: Benchmarking solutions showcase
Workshop 2: Benchmarking solutions showcaseWorkshop 2: Benchmarking solutions showcase
Workshop 2: Benchmarking solutions showcaseaaltunalboro
 
Using Technology to Increase Medication Adherence
Using Technology to Increase Medication AdherenceUsing Technology to Increase Medication Adherence
Using Technology to Increase Medication AdherenceTimothy Aungst, Pharm.D.
 
AMA & MGMA Practice Innovation Challenge Winners
AMA & MGMA Practice Innovation Challenge WinnersAMA & MGMA Practice Innovation Challenge Winners
AMA & MGMA Practice Innovation Challenge Winnershealth2dev
 
Medicines optimisation, pop up uni, 9am, 3 september 2015
Medicines optimisation, pop up uni, 9am, 3 september 2015Medicines optimisation, pop up uni, 9am, 3 september 2015
Medicines optimisation, pop up uni, 9am, 3 september 2015NHS England
 
Patient Experience Measures: Past and Future
Patient Experience Measures: Past and FuturePatient Experience Measures: Past and Future
Patient Experience Measures: Past and FutureBivarus
 

Mais procurados (20)

Closing the Loop: Strategies to Extend Care in the ED
Closing the Loop: Strategies to Extend Care in the EDClosing the Loop: Strategies to Extend Care in the ED
Closing the Loop: Strategies to Extend Care in the ED
 
UK Presentation September 2014 pdf
UK Presentation September 2014  pdfUK Presentation September 2014  pdf
UK Presentation September 2014 pdf
 
Quality Use of Medicines
Quality Use of MedicinesQuality Use of Medicines
Quality Use of Medicines
 
The Beryl Institute 2013 State of the Patient Experience Benchmarking Study
The Beryl Institute 2013 State of the Patient Experience Benchmarking StudyThe Beryl Institute 2013 State of the Patient Experience Benchmarking Study
The Beryl Institute 2013 State of the Patient Experience Benchmarking Study
 
Mhealth for improved medication adherence
Mhealth for improved medication adherenceMhealth for improved medication adherence
Mhealth for improved medication adherence
 
The NHS’ vision for medicines optimisation - the role for pharma in driving ...
The NHS’ vision for medicines optimisation -  the role for pharma in driving ...The NHS’ vision for medicines optimisation -  the role for pharma in driving ...
The NHS’ vision for medicines optimisation - the role for pharma in driving ...
 
Gamification as a means to manage chronic disease
Gamification as a means to manage chronic diseaseGamification as a means to manage chronic disease
Gamification as a means to manage chronic disease
 
London Final Copy
London Final CopyLondon Final Copy
London Final Copy
 
Emerging Technologies for Patient Engagement and Mobile Health
Emerging Technologies for Patient Engagement and Mobile HealthEmerging Technologies for Patient Engagement and Mobile Health
Emerging Technologies for Patient Engagement and Mobile Health
 
The 5 big pitfalls to avoid for successful patient support programmes", by Na...
The 5 big pitfalls to avoid for successful patient support programmes", by Na...The 5 big pitfalls to avoid for successful patient support programmes", by Na...
The 5 big pitfalls to avoid for successful patient support programmes", by Na...
 
Medicines Reconciliation Needs You!
Medicines Reconciliation Needs You!Medicines Reconciliation Needs You!
Medicines Reconciliation Needs You!
 
Genesis Presentation
Genesis PresentationGenesis Presentation
Genesis Presentation
 
Making the Business Case for Hospital RPM/Care Coordination Programs
Making the Business Case for Hospital RPM/Care Coordination ProgramsMaking the Business Case for Hospital RPM/Care Coordination Programs
Making the Business Case for Hospital RPM/Care Coordination Programs
 
Automating ED Patient Follow-Up: INFOGRAPHIC
Automating ED Patient Follow-Up: INFOGRAPHICAutomating ED Patient Follow-Up: INFOGRAPHIC
Automating ED Patient Follow-Up: INFOGRAPHIC
 
2015 ihi international forum shadowing poster
2015 ihi international forum shadowing poster2015 ihi international forum shadowing poster
2015 ihi international forum shadowing poster
 
Workshop 2: Benchmarking solutions showcase
Workshop 2: Benchmarking solutions showcaseWorkshop 2: Benchmarking solutions showcase
Workshop 2: Benchmarking solutions showcase
 
Using Technology to Increase Medication Adherence
Using Technology to Increase Medication AdherenceUsing Technology to Increase Medication Adherence
Using Technology to Increase Medication Adherence
 
AMA & MGMA Practice Innovation Challenge Winners
AMA & MGMA Practice Innovation Challenge WinnersAMA & MGMA Practice Innovation Challenge Winners
AMA & MGMA Practice Innovation Challenge Winners
 
Medicines optimisation, pop up uni, 9am, 3 september 2015
Medicines optimisation, pop up uni, 9am, 3 september 2015Medicines optimisation, pop up uni, 9am, 3 september 2015
Medicines optimisation, pop up uni, 9am, 3 september 2015
 
Patient Experience Measures: Past and Future
Patient Experience Measures: Past and FuturePatient Experience Measures: Past and Future
Patient Experience Measures: Past and Future
 

Destaque

Heuser-Desmond
Heuser-DesmondHeuser-Desmond
Heuser-DesmondOPUNITE
 
Joseph Paduda
Joseph PadudaJoseph Paduda
Joseph PadudaOPUNITE
 
Carol Boyd
Carol BoydCarol Boyd
Carol BoydOPUNITE
 
Mike Townsend
Mike TownsendMike Townsend
Mike TownsendOPUNITE
 
Michelle Lipinski
Michelle LipinskiMichelle Lipinski
Michelle LipinskiOPUNITE
 
Robert Sproul
Robert SproulRobert Sproul
Robert SproulOPUNITE
 
Gary Martin2
Gary Martin2Gary Martin2
Gary Martin2OPUNITE
 
Leslie Balonick
Leslie BalonickLeslie Balonick
Leslie BalonickOPUNITE
 
Dr. Ileana Arias
Dr. Ileana AriasDr. Ileana Arias
Dr. Ileana AriasOPUNITE
 
CLAAD/ Safe BTW
CLAAD/ Safe BTWCLAAD/ Safe BTW
CLAAD/ Safe BTWOPUNITE
 
Richard Victor
Richard VictorRichard Victor
Richard VictorOPUNITE
 
Gary Franklin
Gary FranklinGary Franklin
Gary FranklinOPUNITE
 
Benson-Marshall-Matthew
Benson-Marshall-MatthewBenson-Marshall-Matthew
Benson-Marshall-MatthewOPUNITE
 
Sarah Melton
Sarah MeltonSarah Melton
Sarah MeltonOPUNITE
 
Karen Perry
Karen PerryKaren Perry
Karen PerryOPUNITE
 
Michael-Ward
Michael-WardMichael-Ward
Michael-WardOPUNITE
 
Alex Cahana
Alex CahanaAlex Cahana
Alex CahanaOPUNITE
 
Rollin Gallagher
Rollin GallagherRollin Gallagher
Rollin GallagherOPUNITE
 
Andrew Kolodny
Andrew KolodnyAndrew Kolodny
Andrew KolodnyOPUNITE
 

Destaque (20)

Heuser-Desmond
Heuser-DesmondHeuser-Desmond
Heuser-Desmond
 
Joseph Paduda
Joseph PadudaJoseph Paduda
Joseph Paduda
 
Carol Boyd
Carol BoydCarol Boyd
Carol Boyd
 
Mike Townsend
Mike TownsendMike Townsend
Mike Townsend
 
Michelle Lipinski
Michelle LipinskiMichelle Lipinski
Michelle Lipinski
 
Robert Sproul
Robert SproulRobert Sproul
Robert Sproul
 
Gary Martin2
Gary Martin2Gary Martin2
Gary Martin2
 
Leslie Balonick
Leslie BalonickLeslie Balonick
Leslie Balonick
 
Dr. Ileana Arias
Dr. Ileana AriasDr. Ileana Arias
Dr. Ileana Arias
 
CLAAD/ Safe BTW
CLAAD/ Safe BTWCLAAD/ Safe BTW
CLAAD/ Safe BTW
 
Richard Victor
Richard VictorRichard Victor
Richard Victor
 
Gary Franklin
Gary FranklinGary Franklin
Gary Franklin
 
Benson-Marshall-Matthew
Benson-Marshall-MatthewBenson-Marshall-Matthew
Benson-Marshall-Matthew
 
Sarah Melton
Sarah MeltonSarah Melton
Sarah Melton
 
Ismposter
Ismposter Ismposter
Ismposter
 
Karen Perry
Karen PerryKaren Perry
Karen Perry
 
Michael-Ward
Michael-WardMichael-Ward
Michael-Ward
 
Alex Cahana
Alex CahanaAlex Cahana
Alex Cahana
 
Rollin Gallagher
Rollin GallagherRollin Gallagher
Rollin Gallagher
 
Andrew Kolodny
Andrew KolodnyAndrew Kolodny
Andrew Kolodny
 

Semelhante a Opioid Dependence: Strategies for Health Plans to Improve Care

LeanApproach_MedicationOrder_DispensingProcess
LeanApproach_MedicationOrder_DispensingProcessLeanApproach_MedicationOrder_DispensingProcess
LeanApproach_MedicationOrder_DispensingProcessS CG, PMP®, PMI-RMP®
 
Kuperman Health Information Exchange & Care Coordination
Kuperman Health Information Exchange & Care CoordinationKuperman Health Information Exchange & Care Coordination
Kuperman Health Information Exchange & Care CoordinationTrimed Media Group
 
Paradigm shift-.pptx
Paradigm shift-.pptxParadigm shift-.pptx
Paradigm shift-.pptxssuser179662
 
Rx15 pdmp wed_1115_1_kreiner_2ringwalt
Rx15 pdmp wed_1115_1_kreiner_2ringwaltRx15 pdmp wed_1115_1_kreiner_2ringwalt
Rx15 pdmp wed_1115_1_kreiner_2ringwaltOPUNITE
 
Rx15 clinical tues_1115_1_porathwaller-robeson_2fan-lewis-noonan
Rx15 clinical tues_1115_1_porathwaller-robeson_2fan-lewis-noonanRx15 clinical tues_1115_1_porathwaller-robeson_2fan-lewis-noonan
Rx15 clinical tues_1115_1_porathwaller-robeson_2fan-lewis-noonanOPUNITE
 
How to Define Effective and Efficient Real World Trials
How to Define Effective and Efficient Real World TrialsHow to Define Effective and Efficient Real World Trials
How to Define Effective and Efficient Real World TrialsTodd Berner MD
 
How to design effective and efficient real world trials TB Evidence 2014 10.2...
How to design effective and efficient real world trials TB Evidence 2014 10.2...How to design effective and efficient real world trials TB Evidence 2014 10.2...
How to design effective and efficient real world trials TB Evidence 2014 10.2...Todd Berner MD
 
Rx15 treat tues_330_1_manns_2weiss_3ghitza_4campbell
Rx15 treat tues_330_1_manns_2weiss_3ghitza_4campbellRx15 treat tues_330_1_manns_2weiss_3ghitza_4campbell
Rx15 treat tues_330_1_manns_2weiss_3ghitza_4campbellOPUNITE
 
Rx15 treat tues_200_1_baxter_2barnes_3jeter_4kirsh
Rx15 treat tues_200_1_baxter_2barnes_3jeter_4kirshRx15 treat tues_200_1_baxter_2barnes_3jeter_4kirsh
Rx15 treat tues_200_1_baxter_2barnes_3jeter_4kirshOPUNITE
 
Pharmacist Interventions and Medication Reviews at Care Homes - Improving Med...
Pharmacist Interventions and Medication Reviews at Care Homes - Improving Med...Pharmacist Interventions and Medication Reviews at Care Homes - Improving Med...
Pharmacist Interventions and Medication Reviews at Care Homes - Improving Med...Health Innovation Wessex
 
Generating Quality Data through Collaborative Research with an ACO
Generating Quality Data through Collaborative Research with an ACOGenerating Quality Data through Collaborative Research with an ACO
Generating Quality Data through Collaborative Research with an ACOTodd Berner MD
 
The Role of RWE in Drug Development_4Jun2015_final
The Role of RWE in Drug Development_4Jun2015_finalThe Role of RWE in Drug Development_4Jun2015_final
The Role of RWE in Drug Development_4Jun2015_finalBilly Franks
 
Web only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiro
Web only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiroWeb only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiro
Web only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiroOPUNITE
 

Semelhante a Opioid Dependence: Strategies for Health Plans to Improve Care (20)

Clinical pharmacy.pptx
Clinical pharmacy.pptxClinical pharmacy.pptx
Clinical pharmacy.pptx
 
LeanApproach_MedicationOrder_DispensingProcess
LeanApproach_MedicationOrder_DispensingProcessLeanApproach_MedicationOrder_DispensingProcess
LeanApproach_MedicationOrder_DispensingProcess
 
Medication adherence
Medication adherenceMedication adherence
Medication adherence
 
Kuperman Health Information Exchange & Care Coordination
Kuperman Health Information Exchange & Care CoordinationKuperman Health Information Exchange & Care Coordination
Kuperman Health Information Exchange & Care Coordination
 
Clinical pharmacy
Clinical pharmacyClinical pharmacy
Clinical pharmacy
 
In patient care
In patient careIn patient care
In patient care
 
Paradigm shift-.pptx
Paradigm shift-.pptxParadigm shift-.pptx
Paradigm shift-.pptx
 
Rx15 pdmp wed_1115_1_kreiner_2ringwalt
Rx15 pdmp wed_1115_1_kreiner_2ringwaltRx15 pdmp wed_1115_1_kreiner_2ringwalt
Rx15 pdmp wed_1115_1_kreiner_2ringwalt
 
Rx15 clinical tues_1115_1_porathwaller-robeson_2fan-lewis-noonan
Rx15 clinical tues_1115_1_porathwaller-robeson_2fan-lewis-noonanRx15 clinical tues_1115_1_porathwaller-robeson_2fan-lewis-noonan
Rx15 clinical tues_1115_1_porathwaller-robeson_2fan-lewis-noonan
 
How to Define Effective and Efficient Real World Trials
How to Define Effective and Efficient Real World TrialsHow to Define Effective and Efficient Real World Trials
How to Define Effective and Efficient Real World Trials
 
How to design effective and efficient real world trials TB Evidence 2014 10.2...
How to design effective and efficient real world trials TB Evidence 2014 10.2...How to design effective and efficient real world trials TB Evidence 2014 10.2...
How to design effective and efficient real world trials TB Evidence 2014 10.2...
 
Rx15 treat tues_330_1_manns_2weiss_3ghitza_4campbell
Rx15 treat tues_330_1_manns_2weiss_3ghitza_4campbellRx15 treat tues_330_1_manns_2weiss_3ghitza_4campbell
Rx15 treat tues_330_1_manns_2weiss_3ghitza_4campbell
 
Rx15 treat tues_200_1_baxter_2barnes_3jeter_4kirsh
Rx15 treat tues_200_1_baxter_2barnes_3jeter_4kirshRx15 treat tues_200_1_baxter_2barnes_3jeter_4kirsh
Rx15 treat tues_200_1_baxter_2barnes_3jeter_4kirsh
 
General Discussion on Clinical Pharmacy
General Discussion on Clinical Pharmacy  General Discussion on Clinical Pharmacy
General Discussion on Clinical Pharmacy
 
Pharmacist Interventions and Medication Reviews at Care Homes - Improving Med...
Pharmacist Interventions and Medication Reviews at Care Homes - Improving Med...Pharmacist Interventions and Medication Reviews at Care Homes - Improving Med...
Pharmacist Interventions and Medication Reviews at Care Homes - Improving Med...
 
community pharmacy
community pharmacycommunity pharmacy
community pharmacy
 
Generating Quality Data through Collaborative Research with an ACO
Generating Quality Data through Collaborative Research with an ACOGenerating Quality Data through Collaborative Research with an ACO
Generating Quality Data through Collaborative Research with an ACO
 
The Role of RWE in Drug Development_4Jun2015_final
The Role of RWE in Drug Development_4Jun2015_finalThe Role of RWE in Drug Development_4Jun2015_final
The Role of RWE in Drug Development_4Jun2015_final
 
Web only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiro
Web only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiroWeb only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiro
Web only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiro
 
Robert _highly_organized_primary_care_2
Robert  _highly_organized_primary_care_2Robert  _highly_organized_primary_care_2
Robert _highly_organized_primary_care_2
 

Mais de OPUNITE

Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynoteOPUNITE
 
Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynoteOPUNITE
 
Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynoteOPUNITE
 
Rx16 claad tue-vision_final
Rx16 claad tue-vision_finalRx16 claad tue-vision_final
Rx16 claad tue-vision_finalOPUNITE
 
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerRx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerOPUNITE
 
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingWeb rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingOPUNITE
 
Rx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copyRx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copyOPUNITE
 
Rx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliRx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliOPUNITE
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyOPUNITE
 
Rx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenRx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenOPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingOPUNITE
 
Rx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesRx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesOPUNITE
 
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessWeb only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessOPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingOPUNITE
 
Rx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceRx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceOPUNITE
 
Rx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleRx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleOPUNITE
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattOPUNITE
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanOPUNITE
 
Rx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerRx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerOPUNITE
 
Rx16 tpp wed_200_group
Rx16 tpp wed_200_groupRx16 tpp wed_200_group
Rx16 tpp wed_200_groupOPUNITE
 

Mais de OPUNITE (20)

Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynote
 
Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynote
 
Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynote
 
Rx16 claad tue-vision_final
Rx16 claad tue-vision_finalRx16 claad tue-vision_final
Rx16 claad tue-vision_final
 
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerRx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
 
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingWeb rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
 
Rx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copyRx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copy
 
Rx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliRx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelli
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
 
Rx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenRx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsen
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Rx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesRx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategies
 
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessWeb only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Rx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceRx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2price
 
Rx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleRx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earle
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblatt
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
 
Rx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerRx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_miller
 
Rx16 tpp wed_200_group
Rx16 tpp wed_200_groupRx16 tpp wed_200_group
Rx16 tpp wed_200_group
 

Último

Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxKezaiah S
 
Valproic Acid. (VPA). Antiseizure medication
Valproic Acid.  (VPA). Antiseizure medicationValproic Acid.  (VPA). Antiseizure medication
Valproic Acid. (VPA). Antiseizure medicationMohamadAlhes
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Prerana Jadhav
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...MehranMouzam
 
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptxL1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptxDr Bilal Natiq
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxDr. Dheeraj Kumar
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfDolisha Warbi
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranTara Rajendran
 
Monoclonal antibody production by hybridoma technology
Monoclonal antibody production by hybridoma technologyMonoclonal antibody production by hybridoma technology
Monoclonal antibody production by hybridoma technologyHasnat Tariq
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.ANJALI
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityHarshChauhan475104
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfSreeja Cherukuru
 
Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsMedicoseAcademics
 
World-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptxWorld-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptxEx WHO/USAID
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfMedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfSasikiranMarri
 

Último (20)

Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptx
 
Valproic Acid. (VPA). Antiseizure medication
Valproic Acid.  (VPA). Antiseizure medicationValproic Acid.  (VPA). Antiseizure medication
Valproic Acid. (VPA). Antiseizure medication
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
 
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptxL1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptx
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
 
Monoclonal antibody production by hybridoma technology
Monoclonal antibody production by hybridoma technologyMonoclonal antibody production by hybridoma technology
Monoclonal antibody production by hybridoma technology
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
 
Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes Functions
 
World-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptxWorld-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptx
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfMedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
 

Opioid Dependence: Strategies for Health Plans to Improve Care

  • 1. Opioid Dependence: Health Plan Problems and Strategies Kelly J. Clark, MD, MBA, DFAPA, FASAM Medical Director of Behavioral Health CDPHP, Albany NY
  • 2. Disclosure Statement •  All presenters for this session, Dr. Kelly J. Clark and Dr. Nathaniel P. Katz, have disclosed no relevant, real or apparent personal or professional financial relationships.
  • 3. Learning Objectives: •  1. Identify barriers to responsible pain management that does not contribute to an addiction or to diversion activities. •  2. Outline best practice strategies for patient monitoring to prevent over-prescribing and dispensing. •  3. Explain the importance of coordinating care between health care providers and facilities.
  • 4. Health Plan concerns: •  Value = Quality / Cost •  Behavioral Health = Mental Health, SUDs and Health Behaviors •  Total Cost of Care: –  Primary Care Physician - Hospital –  Specialist - non-MD providers –  Pharmacy - Imaging –  ER and Urgent care - labs
  • 5. Barriers to responsible pain management, or Why might MD s overprescribe? •  Lack of information •  Lack of skill •  External reinforcement
  • 6. Lack of information - What are proper prescription patterns - Which patients are at risk for problems - Whether a patient has demonstrated a problem - Where they can access expert consultation
  • 7. Lack of skill –  Managing patient expectations –  Confronting problematic patient behaviors –  Working collaboratively with other providers –  Using a biopsychosocial approach
  • 8. External reinforcement - Payment models rewarding more quickly writing pills than talking with patients - The Fifth Vital Sign quality metric - Pay for high patient satisfaction
  • 9. Health Plans: Keepers of the Data •  Claims data from all areas: –  Primary Care Physician - Hospital –  Specialist - Labs –  Pharmacy - Imaging –  ER and Urgent care - non-MD providers •  These can be used by individual providers and larger systems to improve care and decrease cost
  • 10. Uses of plan data: population management issues •  Health plan data can show the range of practice patterns in a community •  UDS claims study •  Example emergency department utilization to obtain controlled drug rx
  • 11. Trust, but Verify: the UDS •  Urine Drugs Screens should be like a blood glucose level •  Clinicians need to understand what yields false positives and false negatives •  Who is at risk for substance misuse? –  humans
  • 12. CDPHP •  Regional, non-profit, physician-directed health plan (Albany, NY) •  350,000 covered lives •  All LOB (Medicare, Medicaid, Commercial, ACO)
  • 13. Rates of Drug and/or alcohol screenings –  Continuously enrolled for 12 months –  275 days of fill of any controlled substance (75%) –  drug screening code 80100/80101,G0434,G0431
  • 14. Results : 1 year controlled drug use and UDS •  Medicaid population = 16.8% members •  Medicaid population = 27.9% 1 year Rx •  7.6% of all members with chronic prescriptions had a drug screen within the year
  • 15. Use of ER to obtain controlled drug Rx •  Claims data from first 6 months of 2011 •  ER claims •  Fills for controlled drugs within 2 days of ER visit •  Voluntary inpatient admissions for detoxification or substance abuse rehabilitation
  • 16. 1 visit with a prescription
  • 17. 3 visits with a prescription
  • 18. If an ER doc gives a controlled drug prescription: •  1/58 of our commercial members they give it to use the ER three times January to July •  1/9 of our Medicaid/FHP members they give it to use the ER three times January to July for controlled drugs. •  Or, 1/37 of the Medicaid/FHP members in an ER right now use the ER 3 times for controlled drug from January to July
  • 19. Addiction admissions who obtained rx from ER
  • 20.
  • 21.
  • 22. Intermittent Schedule of Reinforcement - 4.1 pills per rx is the average of the top 10 ER prescribers - 20 pills or more are given in 1/15 total ER prescription - The variability in practice pattern is high, and inversely related to numbers of prescriptions written
  • 23. Plan data can drive education and policy -Educating ER prescribers on practice patterns -Altering policies measuring quality in ERs -Educating all prescribers on need for UDS (including ER docs) -provider systems can work with plans to get the data needed
  • 24. Plan strategies: working with providers to improve monitoring and decrease over-prescribing •  Information exchange •  Care Coordination •  Prior Approval •  Pharmacy management •  Innovative payment programs
  • 25. Health plan tools: Information exchange Primary Care Physician could get info if: • Pt seen in ER • Pt admitted to hospital • Pt filled Prescriptions • Pt seen by specialists • Pt had imaging
  • 26. Health Plan tools: Care Coordination •  calls between providers •  calls to patients •  helping support adherence •  helping support access to ancillary services –  (often social services or behavioral health)
  • 27. Health Plan tools: Prior Approval •  Stops unnecessary re-imaging for pain complaints •  Pharmacy management –  Can be a quality reinforcer
  • 28. Health Plan tools: Pharmacy management •  Monitors for abuse/diversion –  # of prescriptions, # of prescribers, # of pharmacies, # of pills, # of meds in each class •  Quantity limits (# pills, # Rxs) •  Block payments for prescriptions –  Restrict pharmacy, prescribers, pills, facilities •  Feedback to prescribers
  • 29. Health plan tools: Innovative payment programs - bundled payments for multidisciplinary pain programs - buprenorphine spoke-and-wheel - behavioral medicine and/or care coordination as part of PCMH
  • 30. Best Strategies: •  Obtain objective information on your patients: –  UDS –  where they are seen, by whom, with what treatment •  Obtain collaboration with addictionist experts: –  ASAM –  PCSS •  As payment reform happens, work with payers: –  Develop the programs your community needs –  Look at total cost of care ( ER, inpatient, Labs, pharmacy, imaging, as all related to MH/SUDs)
  • 31. Network for assistance •  www.asam.org Addiction physician s medical society •  http://www.pcssprimarycare.org/ Provides addictionist mentors for PCPs